|
|
| | Benzo[h]quinoline-2-methanamine, N-(4-methoxyphenyl)-4-[(4-methoxyphenyl)amino]- Basic information |
| | Benzo[h]quinoline-2-methanamine, N-(4-methoxyphenyl)-4-[(4-methoxyphenyl)amino]- Chemical Properties |
| Boiling point | 633.0±55.0 °C(predicted) | | density | 1.262±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 7.31±0.40(predicted) | | form | Solid | | color | Light yellow to yellow |
| | Benzo[h]quinoline-2-methanamine, N-(4-methoxyphenyl)-4-[(4-methoxyphenyl)amino]- Usage And Synthesis |
| Uses | SDU-071 is a potent and orally active inhibitor of BRD4-p53 inhibitor. SDU-071 inhibits MDA-MB-231 cells proliferation with an IC50 of 10.5 μM. SDU-071 induces cell cycle arrest and apoptosis[1]. | | in vivo | SDU-071 (250 mg/kg for i.g; once daily for 21 days) inhibits tumor growth in a MDA-MB-231 orthotopic mouse xenograft mammary tumor model[1]. | Animal Model: | DA-MB-231 Orthotopic Mouse Xenograft Mammary Tumor Model[1] | | Dosage: | 50 and 250 mg/kg; Once daily for 21 days | | Administration: | Gavage administration (i.g.) | | Result: | Significantly inhibited tumor growth with 49.1% inhibition.
Reduced the Protein levels for BRD4, Mucin5AC, c-Myc, CDK4, and CDK6, upregulated the p21 protein.
|
| | References | [1] Wang S, et al. Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells[J]. ACS Pharmacology & Translational Science, 2024. |
| | Benzo[h]quinoline-2-methanamine, N-(4-methoxyphenyl)-4-[(4-methoxyphenyl)amino]- Preparation Products And Raw materials |
|